HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Shortages Top Of Mind For North American, European and Asia Pacific Consumers

Executive Summary

An overwhelming majority of consumers surveyed by IT consultancy Capgemini are concerned they will not be able to obtain the OTC health products they require or want. In the event of shortages – which are currently affecting consumers across Europe – many respondents said they would substitute with another brand, or in some cases not purchase at all.

You may also be interested in...



Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Reckitt And Haleon

Major Europe-based consumer health players Sanofi Bayer, Reckitt and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q4 2022 results over the coming weeks.

PAGB Calls Out ‘Partial And Incomplete’ Reports Of UK OTC Cough & Cold Shortages

There are no OTC analgesic supply issues in UK despite higher than normal demand, says consumer heathcare industry association PAGB in response to what it labels partial and incomplete reporting” in the country's media. HBW Insight looks at NielsenIQ market data for the week ending 7 Janurary to get behind the headlines. 

Blame The ‘Hamsters’: Germany’s Paediatric Fever Medicine Shortage Worsens

An ongoing crisis in the availability of children's fever medicines in Germany is due to stockpiling – or “hamstering” – by pharmacists and wholesalers, says the country's medicines regulator. This is disputed by not just pharmacists and wholesalers, but also manufacturers, which blame Germany's fixed price system for reimbursable medicines, which includes OTC children's fever medicines. Nevertheless, the German government is seeking to address the real causes of the crisis with a new draft generics law, which is being welcomed by industry. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel